Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report.

Hayashi H, Cho BC, Spigel DR, Girard N, Lee SH, Lu S, Popat S, Yang JC, Passaro A, Baldotto C, Gottfried M, Dias JM, Zimmer Gelatti AC, Wang B, Kam J, Sethi S, Shah S, Kamat M, Zhang J, Curtin JC, William WN Jr, Besse B

Open source

DOI: 10.1016/j.jtho.2026.103894
Published: 2026 Sep
Container: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jtho.2026.103894,
  title = {Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report.},
  author = {Hayashi H and Cho BC and Spigel DR and Girard N and Lee SH and Lu S and Popat S and Yang JC and Passaro A and Baldotto C and Gottfried M and Dias JM and Zimmer Gelatti AC and Wang B and Kam J and Sethi S and Shah S and Kamat M and Zhang J and Curtin JC and William WN Jr and Besse B},
  year = {2026},
  journal = {Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  doi = {10.1016/j.jtho.2026.103894},
  url = {https://doi.org/10.1016/j.jtho.2026.103894}
}

RIS

TY  - JOUR
TI  - Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report.
AU  - Hayashi H
AU  - Cho BC
AU  - Spigel DR
AU  - Girard N
AU  - Lee SH
AU  - Lu S
AU  - Popat S
AU  - Yang JC
AU  - Passaro A
AU  - Baldotto C
AU  - Gottfried M
AU  - Dias JM
AU  - Zimmer Gelatti AC
AU  - Wang B
AU  - Kam J
AU  - Sethi S
AU  - Shah S
AU  - Kamat M
AU  - Zhang J
AU  - Curtin JC
AU  - William WN Jr
AU  - Besse B
PY  - 2026
JO  - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
DO  - 10.1016/j.jtho.2026.103894
UR  - https://doi.org/10.1016/j.jtho.2026.103894
ER  -

APA

H, H., BC, C., DR, S., N, G., SH, L., S, L., S, P., JC, Y., A, P., C, B., M, G., JM, D., AC, Z. G., B, W., J, K., S, S., S, S., M, K., J, Z., JC, C., Jr, W. W., & B, B. (2026). Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. https://doi.org/10.1016/j.jtho.2026.103894

Source records

pubmed · retrieved 2026-09-26T20:49:16.848Z